Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04552288 | Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies | completed | Phase 2 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05571969 |
| Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors |
| terminated |
| Phase 1 |
| 14 |
| Allarity TherapeuticsINDUSTRY |
| 1 |
| Jun 1, 2026 |
| clinicaltrials |
| NCT05663502 | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | recruiting | — | 200 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06400251 | Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07618260 | SIM0613 in Participants With Advanced Solid Tumors(SIM0613-101) | recruiting | Phase 1 | 294 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04145622 | Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | recruiting | Phase 1 / Phase 2 | 250 | Daiichi SankyoINDUSTRY | 2 | May 29, 2026 | clinicaltrials |
| NCT06235983 | A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06246955 | Acceptance and Commitment Therapy and Compassion-Based Virtual Group Therapy to Improve Psychological Wellbeing in Patients With Cancer | recruiting | N/A | 200 | Mayo ClinicOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07480733 | Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 2 | 410 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07615660 | Clinical Study of CVL006 Combination With 9MW2821(CVL006-T1003) | not yet recruiting | Phase 1 / Phase 2 | 108 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | May 29, 2026 | clinicaltrials |
| NCT07615894 | WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I) | not yet recruiting | Phase 1 | 9 | WestVac Biopharma Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT05052268 | XTX202 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 95 | Xilio Development, Inc.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT06351371 | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06357988 | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) | active not recruiting | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06360575 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06360588 | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) | active not recruiting | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06400238 | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06465017 | ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer | terminated | N/A | 149 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06541158 | Transportation for Cancer Care Navigation Tool for Reducing Travel Barriers Among Patients With Solid Tumors Receiving Radiation Therapy(TRACT) | recruiting | N/A | 76 | Emory UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06723041 | Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy | recruiting | N/A | 78 | Mayo ClinicOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07082257 | Precision Performance Status Compared With ECOG Performance Status | terminated | — | 41 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07152236 | Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors | withdrawn | N/A | 0 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07404332 | 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors | recruiting | Phase 1 | 35 | Mohammed MilhemOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07538479 | Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)(NIVALIS) | recruiting | Phase 1 | 24 | West China HospitalOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07611370 | Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers | not yet recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07612085 | A Wearable Biosensor Patch for Non-Invasive Monitoring for Patients Undergoing Abdominal or Chest Surgery | not yet recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07612137 | Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 282 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT07612488 | A Study of CS231295 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 42 | ThalassaX Therapeutics United States LtdINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT03611595 | Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 15 | Peter ZageOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04439149 | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | active not recruiting | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT04439188 | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT04529122 | A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test | completed | — | 7,864 | Hoffmann-La RocheINDUSTRY | 32 | May 27, 2026 | clinicaltrials |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | recruiting | Phase 1 / Phase 2 | 840 | Nuvalent Inc.INDUSTRY | 15 | May 27, 2026 | clinicaltrials |
| NCT05599048 | Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 65 | Robert Bok, MD, PhDOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT05054413 | Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method | recruiting | — | 10 | M.D. Anderson Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07606313 | Phase I Randomized Controlled Trial of Functional Resistance Training in Older Cancer Survivors: The ACES Trial(ACES) | not yet recruiting | N/A | 150 | OHSU Knight Cancer InstituteOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT01628029 | Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer | active not recruiting | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03035604 | Comprehensive Nutritional Geriatric Assessments in Identifying Malnutrition in Older Cancer Participants | active not recruiting | — | 180 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03184038 | Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery | recruiting | N/A | 90 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04381806 | Phase I Study in Advanced Malignancies With 5-ALA | suspended | Phase 1 | 130 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04541108 | Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | active not recruiting | Early Phase 1 | 15 | Presage BiosciencesINDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT05277168 | A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | recruiting | Phase 1 / Phase 2 | 83 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 4 | May 22, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 1, 2026source: clinicaltrials